"..,this raising may act as a cap or lid..."
Agree, Strauss. I've also sold though I retain some in case VHL issues a positive IP statement and Novartis exercises its option over TG 4010.
If I'm still a holder come May 1, I will vote against the Pathway Oncology deal.
If enough join me, the deal won't go ahead.
Nor will the placement.
And nor will the material dilution.
The SP will rise.
As for GGTI-2418, I'm still awaiting an explanation from VHL as to why the Phase 1 trial of the drug was terminated under the auspices of Professor Peter O'Dwyer of the University of Pennsylvania.
- Forums
- ASX - By Stock
- VHL
- Ann: Virax secures $3 million placement
Ann: Virax secures $3 million placement , page-4
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
SPONSORED BY The Market Online